We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

63 hedge funds and large institutions have $614M invested in Design Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

88% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 16

5% more funds holding

Funds holding: 60 → 63 (+3)

3.22% more ownership

Funds ownership: 64.98% → 68.21% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

21% less capital invested

Capital invested by funds: $773M → $614M (-$159M)

Holders
63
Holders Change
+3
Holders Change %
+5%
% of All Funds
0.99%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
30
Reduced
16
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$14.3M
2
ACA
Avoro Capital Advisors
New York
+$8.98M
3
Barclays
Barclays
United Kingdom
+$3.47M
4
EC
EcoR1 Capital
California
+$3.35M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$2.78M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$6.02M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.34M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.27M
4
VC
Vivo Capital
California
-$833K
5
TD Asset Management
TD Asset Management
Ontario, Canada
-$328K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$90.9M – – –
CAM
2
Cormorant Asset Management
Massachusetts
$83.3M -$4.34M -283,459 -5%
BlackRock
3
BlackRock
New York
$50.9M +$14.3M +935,196 +42%
LGM
4
Logos Global Management
California
$45.2M +$383K +25,000 +0.9%
Citadel Advisors
5
Citadel Advisors
Florida
$40.9M – – –
EC
6
EcoR1 Capital
California
$38.3M +$3.35M +218,448 +10%
ACA
7
Avoro Capital Advisors
New York
$35.9M +$8.98M +586,122 +36%
RCM
8
RA Capital Management
Massachusetts
$35.3M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$30.3M +$51.9K +3,391 +0.2%
BBA
10
Baker Bros. Advisors
New York
$23.2M – – –
Janus Henderson Group
11
Janus Henderson Group
United Kingdom
$18.1M +$2.78M +181,784 +19%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$16.6M +$419K +27,366 +3%
Wellington Management Group
13
Wellington Management Group
Massachusetts
$16.1M +$2.2M +143,635 +17%
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$9.27M -$3.27M -213,653 -27%
Principal Financial Group
15
Principal Financial Group
Iowa
$8.78M +$329K +21,458 +4%
VC
16
Vivo Capital
California
$7.7M -$833K -54,402 -10%
State Street
17
State Street
Massachusetts
$6.52M +$939K +61,280 +18%
AG
18
Artal Group
Luxembourg
$6.46M – – –
EAM
19
Eventide Asset Management
Massachusetts
$6.46M – – –
Geode Capital Management
20
Geode Capital Management
Massachusetts
$5.92M +$234K +15,304 +4%
RSCM
21
Rock Springs Capital Management
Maryland
$5.58M +$159K +10,350 +3%
Barclays
22
Barclays
United Kingdom
$3.66M +$3.47M +226,511 New
Northern Trust
23
Northern Trust
Illinois
$3.41M -$15K -981 -0.5%
Norges Bank
24
Norges Bank
Norway
$3.23M – – –
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$3.23M +$536K +35,000 +21%
1
2 3

DSGN Hedge Fund Activity: Q1 2022 in Review

63 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2022, worth a combined $614M — down 21% from $773M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new DSGN positions and 3 closed out — a net gain of 3 holders — while 30 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $14.3M. The largest seller was HHLR Advisors, exiting entirely with an estimated $6.02M sold.

  • 63 institutional investors held Design Therapeutics (DSGN) as of Q1 2022, up from 60 in Q4 2021.
  • Funds reported $614M of Design Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
  • 6 funds opened new Design Therapeutics positions in Q1 2022 and 3 closed out, a net change of +3 holders.
  • The largest Design Therapeutics buyer in Q1 2022 was BlackRock, an estimated $14.3M added.
  • The largest Design Therapeutics seller in Q1 2022 was HHLR Advisors, an estimated $6.02M sold.

Based on aggregated 13F filings for Q1 2022.